Top 5 drugs in the pipeline

September 22, 2020

Some of the top medications were approved this summer, while others are awaiting FDA approval.

Sandoz to supply critical generic injectable meds

July 14, 2020

The pharma maker is partnering with the nonprofit Civica Rx to help reduce shortages in hospitals.

Popular HIV-1 med successful, particularly in order adults

July 07, 2020

Gilead will present new data on virologic suppression in adults 65 years and older at AIDS 2020: Virtual this week.

Major Metformin recalls underway

June 08, 2020

Five pharma markers are recalling the diabetes medication due to the presence of a carcinogenic ingredient.

Express Scripts Report: Top Drug Classes Driving Spending Growth

February 25, 2020

Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.

More Ranitidine recalled, plus another big drug recall

January 10, 2020

Major depression drug recalled over wrong dosage.

Pfizer slashes prices as most pharma makers hike prices in new year

January 03, 2020

Pfizer bucks the trend with as high as 98.5% price cuts.

FDA clears first-in-class migraine drug

January 03, 2020

Approval of Ubrelvy follows several new migraine drugs.

Gilead snags approval for second HIV-1 prevention drug

October 07, 2019

New HIV prevention drug not indicated for women.

FDA approval given for new drug to treat obesity

September 15, 2014

FDA has approved a combination of the generic drugs naltrexone and bupropion (Contrave) for chronic weight management in obese adults (body mass index [BMI] >30 kg/m2). This combination agent has also been approved for use in those patients who are overweight (BMI >27 kg/m2) and have at least one weight-related comorbid condition such as diabetes, hypertension, or dyslipidemia.